The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
New molecular insights into osteosarcoma targeted therapy
Abstract
PURPOSE OF REVIEW: Recent translational studies in osteosarcoma are discussed with the purpose to shed light on the new molecular therapeutic targets. RECENT FINDINGS: The genetic aberrations of vascular endothelial growth factor (VEGF), mammalian target of rapamycin, Wnt signaling pathway, the inactivation of p53, Rb, WWOX genes, and amplification of APEX1, c-myc, RECQL4, RPL8, MDM2, VEGFA might be involved in the pathogenesis of osteosarcoma. The promising therapeutic targets for osteosarcoma patients include: integrin, ezrin, statin, NOTCH/HES1, matrix metalloproteinases (MMPs), m-calpain, and Src, which are involved in tumor cell invasion and metastasis; aldolase A, fructose-bisphosphate, sulfotransferase family 3A, member 1, BCL2-associated athanogene 3, heat shock protein 70 (HSP70), B-cell lymphoma 2-interacting mediator (BIM), polo-like kinase 1, hypoxia inducible factor 1, alpha subunit, minibrain-related kinase, Bcl-xl, caspase-3, midkine, high mobility group box 1 protein (HMGB1), and Beclin1, which are involved in tumor proliferation and apoptosis; met proto-oncogene (hepatocyte growth factor receptor), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, insulin-like growth factor (IGF)-1R, fms-related tyrosine kinase 4, platelet-derived growth factor receptor, beta polypeptide, IGF-I/II, and c-kit, which are involved in tumor growth; endosialin, VEGF, thrombin, and MMPs, which are involved in tumor angiogenesis; transforming growth factor-α/β, parathyroid hormone-like hormone, interleukin-6, interleukin-11, receptor activator of nuclear factor-κB ligand, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, and cathepsin, which are involved in osteoclast function; Myc, HSP90, p-Met, p-Akt, p-STAT3, and cyclin D1, which are transcriptional factors; p-GP, hydroxysteroid (17-beta) dehydrogenase 10, HMGB1, BIM, inorganic phosphate, Bcl-2, PARP, mdm2, p21, Bax, and mitogen-activated protein kinase 1, which are involved in drug sensitivity. Furthermore, microRNAs such as miR-215 are also therapeutic targets. SUMMARY: These translational studies in osteosarcoma have identified new molecular targets for osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 1×
“Despite modern multidisciplinary treatments including chemotherapy and surgery, the 5-year survival rate of osteosarcoma patients remains 60–70% [1,2].”
BackgroundThe Epidemiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_1 · Cited by 1,786
miRNA Signatures Associate with Pathogenesis and Progression of Osteosarcoma
Jones, K. B., Salah, Z., Del Mare, S., Galasso, M., Gaudio, E., Nuovo, G. J., Lovat, F., LeBlanc, K., Palatini, J., Randall, R. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2663 · Cited by 363
The Molecular Pathogenesis of Osteosarcoma: A Review
Broadhead, M. L., Clark, J. C. M., Myers, D. E., Dass, C. R., & Choong, P. F. M. (2011) · Sarcoma · doi:10.1155/2011/959248 · Cited by 346
HMGB1 Promotes Drug Resistance in Osteosarcoma
Huang, J., Ni, J., Liu, K., Yu, Y., Xie, M., Kang, R., Vernon, P., Cao, L., & Tang, D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2001 · Cited by 275
Osaki, M., Takeshita, F., Sugimoto, Y., Kosaka, N., Yamamoto, Y., Yoshioka, Y., Kobayashi, E., Yamada, T., Kawai, A., Inoue, T., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.53 · Cited by 271
Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells
Song, B., Wang, Y., Titmus, M. A., Botchkina, G., Formentini, A., Kornmann, M., & Ju, J. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-96 · Cited by 265
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Rapamycin Inhibits Ezrin-Mediated Metastatic Behavior in a Murine Model of Osteosarcoma
Wan, X., Mendoza, A., Khanna, C., & Helman, L. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3135 · Cited by 216
Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling
Enomoto, M., Hayakawa, S., Itsukushima, S., Ren, D. Y., Matsuo, M., Tamada, K., Oneyama, C., Okada, M., Takumi, T., Nishita, M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.175 · Cited by 179
Bao, Y., Nakagawa, K., Yang, Z., Ikeda, M., Withanage, K., Ishigami-Yuasa, M., Okuno, Y., Hata, S., Nishina, H., & Hata, Y. (2011) · Journal of Biochemistry · doi:10.1093/jb/mvr063 · Cited by 172
Shimizu, T., Ishikawa, T., Sugihara, E., Kuninaka, S., Miyamoto, T. K., Mabuchi, Y., Matsuzaki, Y., Tsunoda, T., Miya, F., Morioka, H., et al. (2010) · Oncogene · doi:10.1038/onc.2010.312 · Cited by 170
Inactive Wnt/β‐catenin pathway in conventional high‐grade osteosarcoma
Cai, Y., Mohseny, A. B., Karperien, M., Hogendoorn, P. C. W., Zhou, G., & Cleton-Jansen, A. (2009) · The Journal of Pathology · doi:10.1002/path.2628 · Cited by 168
MicroRNA Involvement in Osteosarcoma
Kobayashi, E., Hornicek, F. J., & Duan, Z. (2012) · Sarcoma · doi:10.1155/2012/359739 · Cited by 157
miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma
Cai, C., ZHAO, G.-Y., Tian, L., LIU, L., YAN, K., Ma, Y., Ji, Z., Li, X., Han, K., Gao, J., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1995 · Cited by 152
Liu, L., Li, H., Li, J., Zhong, H., Zhang, H.-C., Chen, J., & Xiao, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.10.117 · Cited by 150
Bim-targeted cancer therapy: A link between drug action and underlying molecular changes
Akiyama, T., Dass, C. R., & Choong, P. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0685 · Cited by 149
Akiyama, T., Dass, C. R., & Choong, P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0530 · Cited by 139
Yang, J., Yang, D., Sun, Y. K., Sun, B., Wang, G., Trent, J. C., Araujo, D. M., Chen, K., & Zhang, W. (2011) · Cancer · doi:10.1002/cncr.26116 · Cited by 125
Self-citationIKKγ protein is a target of BAG3 regulatory activity in human tumor growth
Ammirante, M., Rosati, A., Arra, C., Basile, A. M., Falco, A., Festa, M., Pascale, M. C., d’Avenia, M., Marzullo, L., Belisario, M. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907696107 · Cited by 124
Avnet, S., Sciacca, L., Salerno, M., Gancitano, G., Cassarino, M. F., Longhi, A., Zakikhani, M., Carboni, J. M., Gottardis, M. M., Giunti, A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2645 · Cited by 111
Li, Y., Zhang, J., Ma, D., Zhang, L., Si, M., Yin, H., & Li, J. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08607.x · Cited by 109
Gillings, A. S., Balmanno, K., Wiggins, C. M., Johnson, M. A., & Cook, S. J. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07329.x · Cited by 108
Zhang, P., Yang, Y., Nolo, R. M., Zweidler‐McKay, P. A., & Hughes, D. P. M. (2010) · Oncogene · doi:10.1038/onc.2010.62 · Cited by 107
Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma
Morioka, K., Tanikawa, C., Ochi, K., Daigo, Y., Katagiri, T., Kawano, H., Kawaguchi, H., Myoui, A., Yoshikawa, H., Naka, N., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01165.x · Cited by 107
Cell surface receptor expression patterns in osteosarcoma
Hassan, S. E., Bekarev, M., Kim, M., Lin, J., Piperdi, S., Gorlick, R. G., & Geller, D. S. (2011) · Cancer · doi:10.1002/cncr.26339 · Cited by 99
The novel HSP90 inhibitor STA‐1474 exhibits biologic activity against osteosarcoma cell lines
McCleese, J., Bear, M. D., Fossey, S. L., Mihalek, R., Foley, K. P., Ying, W., Barsoum, J., & London, C. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24660 · Cited by 83
Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin
Wan, X., Kim, S. Y., Guenther, L. M., Mendoza, A., Briggs, J., Yeung, C., Currier, D. G., Zhang, H., Mackall, C. L., Li, W.-J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.206 · Cited by 80
Lenos, K., Grawenda, A. M., Lodder, K., Kuijjer, M. L., Teunisse, A. F. A. S., Repapi, E., Grochola, L. F., Bartel, F., Hogendoorn, P. C. W., Wuerl, P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0215 · Cited by 66
Maire, G., Yoshimoto, M., Chilton‐MacNeill, S., Thorner, P. S., Zieleńska, M., & Squire, J. A. (2009) · Neoplasia · doi:10.1593/neo.81384 · Cited by 64
Brambilla, D., Zamboni, S., Federici, C., Lugini, L., Lozupone, F., Milito, A. D., Cecchetti, S., Cianfriglia, M., & Fais, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.26285 · Cited by 64
CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis
Fromigué, O., Hamidouche, Z., Vaudin, P., Lecanda, F., Patiño‐García, A., Barbry, P., Mari, B. P., & Marie, P. J. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.343 · Cited by 62
Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma
Lu, B.-J., WANG, Y.-Q., WEI, X.-J., Rong, L., Dong, W., YAN, C.-M., WANG, D.-J., & Sun, J. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.772 · Cited by 60
Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma
Yang, J., Cogdell, D. E., Yang, D., Hu, L., Li, H., Zheng, H., Du, X., Pang, Y., Trent, J. C., Chen, K., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.018 · Cited by 57
Self-citationYang, J., Yang, D., Cogdell, D. E., Du, X., Li, H., Pang, Y., Sun, Y. K., Hu, L., Sun, B., Trent, J. C., et al. (2010) · Technology in Cancer Research & Treatment · doi:10.1177/153303461000900205 · Cited by 53
Self-citationLiontos, M., Niforou, K., Velimezi, G., Vougas, K. N., Evangelou, K., Apostolopoulou, K., Vrtěl, R., Damalas, A. F., Kontovazenitis, P., Kotsinas, A., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081160 · Cited by 53
Chen, Z., Huang, C., Yang, Y., Ding, Y., Ouyang, H., Zhang, Y., & Xu, M. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.164 · Cited by 53
The kinase Mirk is a potential therapeutic target in osteosarcoma
Yang, C., Ji, D., Weinstein, E. J., Choy, E., Hornicek, F. J., Wood, K. B., Liu, X., Mankin, H. J., & Duan, Z. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp330 · Cited by 50
Spina, A., Sorvillo, L., Maiolo, F. D., Esposito, A., D’Auria, R., Gesto, D. D., Chiosi, E., & Naviglio, S. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24124 · Cited by 49
Salas, S., Jézéquel, P., Campion, L., Deville, J., Chibon, F., Bartoli, C., Gentet, J., Guérin‐Charbonnel, C., Gouraud, W., Voutsinos‐Porche, B., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24457 · Cited by 48
Wang, Y., Wang, Z.-X., Qiu, Y., Xiong, J., Chen, Y., Miao, D., & De, W. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0064-y · Cited by 45
High Wnt Signaling Represses the Proapoptotic Proteoglycan syndecan-2 in Osteosarcoma Cells
Dieudonné, F., Marion, A., Haÿ, E., Marie, P. J., & Modrowski, D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0090 · Cited by 45
Wang, Y., Zheng, L., Ma, B., et al. (2010) · Acta Histochemica · doi:10.1016/j.acthis.2010.03.002 · Cited by 37
Ichikawa, J., Cole, H. A., Magnussen, R. A., Mignemi, N. A., Butler, M., Holt, G. E., O'Rear, L., Yuasa, M., Pabla, B., Haro, H., et al. (2012) · Cancer · doi:10.1002/cncr.26518 · Cited by 36
Functional genome screen for therapeutic targets of osteosarcoma
Yamaguchi, U., Honda, K., Satow, R., Kobayashi, E., Nakayama, R. T., Ichikawa, H., Shoji, A., Shitashige, M., Masuda, M., Kawai, A., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01310.x · Cited by 30
HIF-1α induced by β-elemene protects human osteosarcoma cells from undergoing apoptosis
Liang, D., Yang, M., Guo, B., Yang, L., Cao, J., & Zhang, X. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1256-5 · Cited by 30
Xie, X., Yang, D., Ye, Z., & Tao, H. (2006) · Cancer Investigation · doi:10.1080/07357900500449520 · Cited by 29
Endosialin expression in side populations in human sarcoma cell lines
Rouleau, C., Sancho, J., Campos‐Rivera, J., & Teicher, B. A. (2011) · Oncology Letters · doi:10.3892/ol.2011.478 · Cited by 21
Exploration of a new drug that targets YAP
Fujii, M. (2012) · The Journal of Biochemistry · doi:10.1093/jb/mvs072 · Cited by 14
Cited by
Tsai, H.-C., Su, H.-L., Huang, C.-Y., Fong, Y.-C., Hsu, C.-J., & Tang, C.-H. (2014) · Oncotarget · doi:10.18632/oncotarget.1998 · Cited by 78
Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma
Ge, W., Li, J., Fan, W., Xu, D., & Sun, S. (2017) · Tumor Biology · doi:10.1177/1010428317715643 · Cited by 45
Gene expression profiling analysis of osteosarcoma cell lines
SUN, L., LI, J., & YAN, B. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3958 · Cited by 27
Metadata
- Authors
- Yang, J., & Zhang, W.
- Venue
- Current Opinion in Oncology
- Published
- 2013-07
- Volume
- 25
- Issue
- 4
- Pages
- 398-406
- ISSN
- 1040-8746 (ISSN-L)
- OpenAlex
- W1996543107
- Cited by
- 262
- References
- 50
- FWCI
- 27.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.